Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma

  • Lee, Eonju (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Tae Gyu (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Hee Chul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yu, Jeong Il (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lim, Do Hoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Nam, Heerim (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Hyebin (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Joon Hyeok (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2015.07.09
  • Accepted : 2015.09.15
  • Published : 2015.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate the outcomes of patients with spinal metastases from hepatocellular carcinoma (HCC), who were treated by stereotactic body radiotherapy (SBRT). Materials and Methods: This retrospective study evaluated 23 patients who underwent SBRT from October 2008 to August 2012 for 36 spinal metastases from HCC. SBRT consisted of approximately 2 fractionation schedules, which were 18 to 40 Gy in 1 to 4 fractions for group A lesions (n = 15) and 50 Gy in 10 fractions for group B lesions (n = 21). Results: The median follow-up period was 7 months (range, 2 to 16 months). Seven patients developed grade 1 or 2 gastrointestinal toxicity, and one developed grade 2 leucopenia. Compression fractures occurred in association with 25% of the lesions, with a median time to fracture of 2 months. Pain relief occurred in 92.3% and 68.4% of group A and B lesions, respectively. Radiologic response (complete and partial response) occurred in 80.0% and 61.9% of group A and B lesions, respectively. The estimated 1-year spinal-tumor progression-free survival rate was 78.5%. The median overall survival period and 1-year overall survival rate were 9 months (range, 2 to 16 months) and 25.7%, respectively. Conclusion: SBRT for spinal metastases from HCC is well tolerated and effective at providing pain relief and radiologic response. Because compression fractures develop at a high rate following SBRT for spinal metastases from primary HCC, careful follow up of the patient is required.

Keywords

References

  1. Klimo P Jr, Schmidt MH. Surgical management of spinal metastases. Oncologist 2004;9:188-96. https://doi.org/10.1634/theoncologist.9-2-188
  2. Wong DA, Fornasier VL, MacNab I. Spinal metastases: the obvious, the occult, and the impostors. Spine (Phila Pa 1976) 1990;15:1-4. https://doi.org/10.1097/00007632-199001000-00001
  3. Byrne TN. Spinal cord compression from epidural metastases. N Engl J Med 1992;327:614-9. https://doi.org/10.1056/NEJM199208273270907
  4. Schaberg J, Gainor BJ. A profile of metastatic carcinoma of the spine. Spine (Phila Pa 1976) 1985;10:19-20. https://doi.org/10.1097/00007632-198501000-00003
  5. Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 2005;23:3366-75. https://doi.org/10.1200/JCO.2005.04.754
  6. Hamilton AJ, Lulu BA, Fosmire H, Stea B, Cassady JR. Preliminary clinical experience with linear accelerator-based spinal stereotactic radiosurgery. Neurosurgery 1995;36:311-9. https://doi.org/10.1227/00006123-199502000-00010
  7. Jin JY, Chen Q, Jin R, et al. Technical and clinical experience with spine radiosurgery: a new technology for management of localized spine metastases. Technol Cancer Res Treat 2007;6:127-33. https://doi.org/10.1177/153303460700600209
  8. Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 2007;7:151-60. https://doi.org/10.3171/SPI-07/08/151
  9. Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 2007;32:193-9. https://doi.org/10.1097/01.brs.0000251863.76595.a2
  10. Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976) 2009;34(22 Suppl):S78-92. https://doi.org/10.1097/BRS.0b013e3181b8b6f5
  11. Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005;20:1781-7. https://doi.org/10.1111/j.1440-1746.2005.03919.x
  12. Fukutomi M, Yokota M, Chuman H, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2001;13:1083-8. https://doi.org/10.1097/00042737-200109000-00015
  13. Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005;25:261-5. https://doi.org/10.1111/j.1478-3231.2005.01094.x
  14. Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:1025-33. https://doi.org/10.1046/j.1440-1746.1999.01994.x
  15. He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 2009;115:2710-20. https://doi.org/10.1002/cncr.24300
  16. Kim S, Chun M, Wang H, et al. Bone metastasis from primary hepatocellular carcinoma: characteristics of soft tissue formation. Cancer Res Treat 2007;39:104-8. https://doi.org/10.4143/crt.2007.39.3.104
  17. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S42-9. https://doi.org/10.1016/j.ijrobp.2009.04.095
  18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16. https://doi.org/10.1093/jnci/92.3.205
  19. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S. https://doi.org/10.2967/jnumed.108.057307
  20. Chao ST, Koyfman SA, Woody N, et al. Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases. Int J Radiat Oncol Biol Phys 2012;82:1738-43. https://doi.org/10.1016/j.ijrobp.2011.02.019
  21. Kaizu T, Karasawa K, Tanaka Y, et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol 1998;93:2167-71. https://doi.org/10.1111/j.1572-0241.1998.00614.x
  22. Ahmed KA, Stauder MC, Miller RC, et al. Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys 2012;82:e803-9. https://doi.org/10.1016/j.ijrobp.2011.11.036
  23. Gerszten PC, Burton SA, Quinn AE, Agarwala SS, Kirkwood JM. Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg 2005;83:213-21. https://doi.org/10.1159/000091952
  24. Ryu S, Rock J, Rosenblum M, Kim JH. Patterns of failure after single-dose radiosurgery for spinal metastasis. J Neurosurg 2004;101 Suppl 3:402-5. https://doi.org/10.3171/jns.2004.101.3.0402
  25. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 2008;71:484-90. https://doi.org/10.1016/j.ijrobp.2007.11.046
  26. Nguyen QN, Shiu AS, Rhines LD, et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010;76:1185-92. https://doi.org/10.1016/j.ijrobp.2009.03.062
  27. Haley ML, Gerszten PC, Heron DE, Chang YF, Atteberry DS, Burton SA. Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis. J Neurosurg Spine 2011;14:537-42. https://doi.org/10.3171/2010.12.SPINE10233
  28. Cunha MV, Al-Omair A, Atenafu EG, et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys 2012;84:e343-9. https://doi.org/10.1016/j.ijrobp.2012.04.034
  29. Rose PS, Laufer I, Boland PJ, et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 2009;27:5075-9. https://doi.org/10.1200/JCO.2008.19.3508
  30. Boehling NS, Grosshans DR, Allen PK, et al. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine 2012;16:379-86. https://doi.org/10.3171/2011.11.SPINE116
  31. van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW; Dutch Bone Metastasis Study Group. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer 2005;103:320-8. https://doi.org/10.1002/cncr.20756
  32. Hoskin PJ, Grover A, Bhana R. Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. Radiother Oncol 2003;68:175-80. https://doi.org/10.1016/S0167-8140(03)00191-9
  33. Tokuhashi Y, Ajiro Y, Umezawa N. Outcome of treatment for spinal metastases using scoring system for preoperative evaluation of prognosis. Spine (Phila Pa 1976) 2009;34:69-73. https://doi.org/10.1097/BRS.0b013e3181913f19
  34. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine (Phila Pa 1976) 2001;26:298-306. https://doi.org/10.1097/00007632-200102010-00016

Cited by

  1. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis vol.22, pp.30, 2016, https://doi.org/10.3748/wjg.v22.i30.6851
  2. Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05) vol.11, pp.3, 2015, https://doi.org/10.1371/journal.pone.0152642
  3. Spine Metastasis Practice Patterns among Korean, Chinese, and Japanese Radiation Oncologists: A Multinational Online Survey Study vol.58, pp.1, 2015, https://doi.org/10.1093/jrr/rrw089
  4. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma vol.8, pp.9, 2015, https://doi.org/10.18632/oncotarget.14858
  5. Establishment of a Disease-Specific Graded Prognostic Assessment for Hepatocellular Carcinoma Patients with Spinal Metastasis vol.11, pp.4, 2015, https://doi.org/10.5009/gnl16486
  6. Stereotactic ablative body radiotherapy for spinal metastasis from hepatocellular carcinoma: its oncologic outcomes and risk of vertebral compression fracture vol.8, pp.42, 2015, https://doi.org/10.18632/oncotarget.20529
  7. The 18 F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes vol.13, pp.9, 2015, https://doi.org/10.1371/journal.pone.0204918
  8. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm vol.24, pp.45, 2015, https://doi.org/10.3748/wjg.v24.i45.5081
  9. Efficacy and safety of different fractions in stereotactic body radiotherapy for spinal metastases: A systematic review vol.8, pp.14, 2015, https://doi.org/10.1002/cam4.2546
  10. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma vol.25, pp.20, 2019, https://doi.org/10.3748/wjg.v25.i20.2416
  11. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma vol.8, pp.16, 2015, https://doi.org/10.1002/cam4.2570